HOME
Better Health, Brighter Future
Newsroom Careers Investors United States
HOME
About Takeda How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information Takeda in the U.S. Worldwide Offices Executive Leadership
Corporate Philosophy
Contact Us

Our Business Takeda continues its transformation into an agile and innovative global pharmaceutical leader, serving the needs of patients and physicians worldwide. Learn more
Patient Services
U.S. Product List
Research & Development Our Pipeline
Therapeutic Areas
Our Stories A selection of stories related to Innovation, Caring and Heritage Learn more
Innovation In Their Shoes The Key Elements at the Heart of Our Innovation Partnerships as Catalysts for Innovation
Caring Medicine for the World
Heritage Keys to Aging Gracefully
Takeda's CSR Takeda is committed to creating corporate value by developing outstanding pharmaceutical products and conducting corporate citizenship activities. Learn more
Commitment to Community Our Environment
Culture of Compliance Federal CPSIA State Open Payments and Transparency Reporting
Diversity and Inclusion
Independent Medical Education Grants
Takeda Pricing Philosophy
Lobbying & Political Contributions
Patient Assistance
ADHD Medicines Misuse
HOME Newsroom News Releases
Share:
News Releases NATPARA Updates COVID-19 Updates

News Releases

April 2020

April 23, 2020 4/23/2020 ProThera Biologics and Takeda Enter Global Licensing Agreement
April 16, 2020 4/16/2020 USBU COVID-19 Supply Statement

March 2020

March 25, 2020 3/25/2020 Supporting Our Communities During the COVID-19 Outbreak
March 12, 2020 3/12/2020 Supporting Our Healthcare Providers During COVID-19
March 6, 2020 3/6/2020 Update on US Recall of Two Lots of VONVENDI® [von Willebrand factor (recombinant)]

February 2020

February 25, 2020 2/25/2020 Takeda Issues US Recall of Two Lots of VONVENDI
February 10, 2020 2/10/2020 Takeda to Present Research Advances in Rare Lysosomal Storage Disorders at 16th Annual WORLDSymposiumâ„¢ 2020

December 2019

December 20, 2019 12/20/2019 Takeda Receives Complete Response Letter from U.S. FDA for the Investigational Subcutaneous Formulation of ENTYVIO® (vedolizumab) as a Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis
  • 1
  • 2
  • 3
  • 4
  • 5
TOP
Terms of Use Privacy Notice CONTACT US PATENTS

Copyright 2019 Takeda Pharmaceutical Company Limited. All rights reserved.

Certified Top Employer

Connect with us:
linkedin twitter
United States

Copyright 2019 Takeda Pharmaceutical Company Limited. All rights reserved.

Certified Top Employer

 

You are about to leave www.Takeda.com/en-us and be redirected to another Takeda domain.